Beyond KOMET-007: What’s Next for Ziftomenib in AML

In an interview with Targeted Oncology, Amer Zeidan, MBBS, MHS, chief, division of hematologic malignancies at Yale Cancer Center and professor of medicine at Yale School of Medicine discusses the expanding clinical development program for the menin inhibitor ziftomenib (Komzifti) and its potential to reshape treatment strategies for acute myeloid leukemia (AML). The discussion follows promising frontline data from the phase 1b/2 KOMET-007 trial (NCT05735184) presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden.

Watch part 1, part 2, and part 3 of Dr Zeidan’s interview.

As evidence supporting menin inhibition continues to grow, investigators are evaluating ziftomenib across multiple treatment settings and combination regimens. Zeidan reviews ongoing studies examining the agent alongside intensive chemotherapy approaches beyond 7+3, including FLAG-IDA–based regimens, as well as combinations with targeted therapies such as FLT3 inhibitors in molecularly defined AML populations.

He also highlights ongoing efforts to pair ziftomenib with gilteritinib (Xospata) in patients with relapsed/refractory FLT3-mutated, NPM1-mutated AML and discusses investigations of the drug in lower-intensity treatment approaches. According to Zeidan, emerging data suggest that the synergistic activity observed with menin inhibition may extend across a range of therapeutic backbones, supporting continued exploration in diverse patient populations.

He also addresses the rationale for selecting 7+3 as the foundation of the ongoing phase 3 KOMET-017 registrational program (NCT07007312), given its widespread use as the standard intensive induction regimen worldwide. Looking ahead, Zeidan discusses the potential implications of a positive phase 3 outcome, noting that successful integration of ziftomenib into frontline treatment could meaningfully alter the standard of care for a substantial proportion of patients with newly diagnosed AML who are eligible for intensive chemotherapy.